Global Contrast Injector Market, By Product (Consumables, Injector Systems, Accessories), Type of Injectors (Single-head Injectors, Dual-head Injectors, and Syringeless Injectors), Application (Radiology, Interventional Radiology, Interventional Cardiology), End User (Hospitals, Diagnostic Imaging Centers) – Industry Trends and Forecast to 2030.
Contrast Injector Market Analysis and Size
According to the World Health Organization (WHO) 2021, cardiovascular diseases (CVDs) are the leading cause of death worldwide. Cardiovascular disease affects an estimated 17.9 million people each year. Strokes and heart attacks cause four out of every five cardiovascular deaths, and one-third of deaths occur in people under 70. The majority of businesses are developing novel products to reduce contrast media waste and gain a competitive advantage. Bracco has developed smart syringeless injectors that can maximise efficiency by using every drop of contrast loaded into the system. Smart injectors record the amount injected as well as the imaging protocol used and transmit the information to the PACS. These continuous technological advancements, as opposed to media injector technology, are expected to drive the market during the forecast period.
Data Bridge Market Research analyses that the contrast injector market which was USD 849.85 million in 2022, is expected to reach USD 1,294.40 million by 2030, at a CAGR of 5.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Contrast Injector Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Product (Consumables, Injector Systems, Accessories), Type of Injectors (Single-head Injectors, Dual-head Injectors, and Syringeless Injectors), Application (Radiology, Interventional Radiology, Interventional Cardiology), End User (Hospitals, Diagnostic Imaging Centers)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
General Electric (U.S.), Vivid Imaging Solutions (U.S.), Hilin Life Products, Inc. (U.S.), Jodas Expoim Pvt. Ltd. (India), Lantheus (U.S.), Magnus Health (U.S.), TAEJOON PHARM (South Korea), Spago Nanomedical AB (Sweden), Guerbet (France), Bracco (Italy), Bayer AG (Germany), Medtron AG (Germany), NemotoKyorindo Co., Ltd. (China), ulrich GmbH & Co. KG (Germany), Sino Medical-Device Technology Co. (China), Apollo RT Co. Ltd. (China)
Contrast injectors have evolved over time from manual injectors with manifolds and stop-cocks to automated versions with greater accuracy and advantages. These automated versions are referred to as auto-injectors. To keep up with today's high-speed medical imaging scanners, auto-injectors can manage the amount of contrast media injected and the rate at which it is absorbed into the patient's body and alert the physician to potential hazards such as air embolisms and possibly extravasations.
Global Contrast Injector Market Dynamics
- Prevalence of cancer with cardiovascular disease (CVD)
The number of people affected by cancer has risen dramatically in recent decades. Furthermore, cardiovascular disease and stroke are the leading causes of death worldwide. According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death worldwide. According to World Health Organization (WHO) projections for 2015, nearly 23.6 million people will die from cardiovascular disease by 2030. Contrast injectors are expected to benefit from an increase in cancer and cardiovascular disease patients, which will lead to an increase in demand for upgraded healthcare facilities and advanced diagnostic imaging methods, driving the market for contrast injector.
- Advances in contrast to media injector technology
The primary factors driving the growth of the contrast injector market are the rising demand for minimally invasive surgeries, technological advancements, and increased regulatory approvals. Several advances in contrast media injector technology have been made to reduce contrast media waste and automate data collection about a patient's dose. For instance, automated injector systems precisely collect the amount of contrast media used. Vendors provide personalised doses for patients based on EMR or PACS data. Syringeless injectors are one such advancement in reducing contrast media waste.
- Rising usage of CT injectors
CT injectors are expected to grow positively as the use of CT systems has increased in recent years. During imaging, these CT systems employ a dual-head injector with two syringes for initial and follow-up contrast doses. Major academic institutions and pharmaceutical companies have been engaged in continuous R&D to develop protocols that assist CT users with the advanced capabilities of newer imaging systems. During the forecast period, the market will benefit from integrating IT and contrast media dose management.
- High costs will derail the growth rate
The market growth is expected to be hampered by the high cost of contrast media injectors during the forecast period. Consumable costs are also recurring because the same syringe and tube cannot be used twice, another factor limiting the future market growth. Tubes and syringes can cost up to US$ 350-500 each, limiting their use by medical professionals.
Furthermore, a lack of knowledge is expected to negatively impact the market during the period under consideration. It is also possible to develop air embolisms during contrast media injection, which can have serious consequences such as heart failure or respiratory failure.
This contrast injector market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the contrast injector market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Contrast Injector Market
The pandemic outbreak caused a slowdown in elective surgical procedures and medical examinations to break the chain and conserve healthcare resources for COVID-19 patients. This, in turn, resulted in a sharp drop in demand for contrast injectors, which are used to control contrast material before diagnostic imaging techniques such as CT or MRI scans. However, as the global situation improves, the market is expected to return to normal.
- In December 2021, Guerbet and Bracco Imaging announced a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.
- In December 2021, Qaelum NV announced a strategic partnership with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with Ulrich Medical's contrast media injectors to support the needs of hospitals and imaging networks.
Global Contrast Injector Market Scope
The contrast injector market is segmented on the basis of product, type of injectors, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Other consumables
- Injector Systems
- CT injectors
- MRI injectors
- Angiography injectors
Type of Injectors
- Single-head Injectors
- Dual-head Injectors
- Syringeless Injectors
- Interventional Radiology
- Interventional Cardiology
- Diagnostic Imaging Centers
Contrast Injector Market Regional Analysis/Insights
The contrast injector market is analysed and market size insights and trends are provided by country, product, type of injectors,application and end user as referenced above.
The countries covered in the contrast injector market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the contrast injector market because of the advanced healthcare facilities and easy access to expert radiologists and surgeons.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the region's developing healthcare infrastructure and rising prevalence of chronic diseases such as orthopaedic diseases, epilepsy, Alzheimer's disease, and cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The contrast injector market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for contrast injector market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the contrast injector market. The data is available for historic period 2011-2021.
Competitive Landscape and Contrast Injector Market Share Analysis
The contrast injector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to contrast injector market.
Some of the major players operating in the contrast injector market are:
- General Electric (U.S.)
- Vivid Imaging Solutions (U.S.)
- Hilin Life Products, Inc. (U.S.)
- Jodas Expoim Pvt. Ltd. (India)
- Lantheus (U.S.)
- Magnus Health (U.S.)
- TAEJOON PHARM (South Korea)
- Spago Nanomedical AB (Sweden)
- Guerbet (France)
- Bracco (Italy)
- Bayer AG (Germany)
- Medtron AG (Germany)
- NemotoKyorindo Co., Ltd. (China)
- ulrich GmbH & Co. KG (Germany)
- Sino Medical-Device Technology Co. (China)
- Apollo RT Co. Ltd. (China)